When heme levels are low, more delta-aminolevulinic acid (ALA) synthase are produced. Causing larger quantities of heme precursors to be fed into the biosynthesis path producing more heme.
Much of the heme biosynthesis pathway is dedicated to constructing the porphyrin molecule.
It is complex, various chemical signals can trigger increased or decreased production. These signals can affect the enzymes themselves or the production of these enzymes, at the genetic level.
Primary biosynthesis sites are the liver and the bone marrow.
Hepatic porphyrias.
Owing to a defect in one of the enzymes of the heme biosynthesis pathway, protoporphyrins or porphyrins (heme precursors) are prevented from proceeding further along the pathway.
Porphobilinogen is an intermediate molecule in the biosynthesis of heme, a component of hemoglobin and other proteins. It is produced in the body through a series of enzymatic reactions in the heme biosynthesis pathway. Elevated levels of porphobilinogen can be found in certain conditions like acute intermittent porphyria.
The underlying cause of all porphyrias is a defective enzyme important to the heme biosynthesis pathway. Porphyrias are inheritable conditions.
Erythropoietic porphyrias (erythropoiesis is the process through which red blood cells are produced).
Hepatoerythopoietic porphyria (HEP) affects heme biosynthesis in both the liver and the bone marrow and appears due to inheriting an autosomal recessive gene.
Porphyria refers to a group of rare, inherited disorders that affect the heme biosynthesis pathway, leading to the accumulation of porphyrins or heme precursors in the body. Symptoms can range from mild to severe and may include abdominal pain, skin sensitivity to light, and neurological issues. Treatment often involves managing symptoms and avoiding triggers.
ALA dehydratase deficiency porphyria (step 2); acute intermittent porphyria (step 3); hereditary coproporphyria (step 6); variegate porphyria (step 7).
Congenital erythropoietic porphyria (step 4); porphyria cutanea tarda (step 5); hepatoerythopoietic porphyria (step 5); erythropoietic protoporphyria (step 8).